Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

101. Deep brain and cortical stimulation for epilepsy. (Full text)

Deep brain and cortical stimulation for epilepsy. Despite optimal medical treatment, including epilepsy surgery, many epilepsy patients have uncontrolled seizures. Since the 1970s interest has grown in invasive intracranial neurostimulation as a treatment for these patients. Intracranial stimulation includes both deep brain stimulation (DBS) (stimulation through depth electrodes) and cortical stimulation (subdural electrodes). This is an updated version of a previous Cochrane review published (...) in 2014.To assess the efficacy, safety and tolerability of DBS and cortical stimulation for refractory epilepsy based on randomized controlled trials (RCTs).We searched the Cochrane Epilepsy Group Specialized Register on 29 September 2015, but it was not necessary to update this search, because records in the Specialized Register are included in CENTRAL. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2016, Issue 11, 5 November 2016), PubMed (5 November

2017 Cochrane PubMed

102. Intravenous immunoglobulins for epilepsy. (Full text)

Intravenous immunoglobulins for epilepsy. Epilepsy is a common neurological condition, with an estimated incidence of 50 per 100,000 persons. People with epilepsy may present with various types of immunological abnormalities, such as low serum immunoglobulin A (IgA) levels, lack of the immunoglobulin G (IgG) subclass and identification of certain types of antibodies. Intravenous immunoglobulin (IVIg) treatment may represent a valuable approach and its efficacy has important implications (...) for epilepsy management. This is an updated version of the original Cochrane review published in Issue 1, 2011.To examine the effects of IVIg on the frequency and duration of seizures, quality of life and adverse effects when used as monotherapy or as add-on treatment for people with epilepsy.For the latest update, we searched the Cochrane Epilepsy Group Specialized Register (2 February 2017), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (2

2017 Cochrane PubMed

103. [Stiripentol for the treatment of severe myoclonic epilepsy in infants (dravet's syndrome)]

[Stiripentol for the treatment of severe myoclonic epilepsy in infants (dravet's syndrome)] [Stiripentol for the treatment of severe myoclonic epilepsy in infants (dravet's syndrome)] [Stiripentol for the treatment of severe myoclonic epilepsy in infants (dravet's syndrome)] Mengarelli C, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mengarelli C, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Ciapponi A, López A, Rey-Ares L. [Stiripentol for the treatment of severe myoclonic epilepsy in infants (dravet's syndrome)] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 522. 2017 Authors' conclusions

2017 Health Technology Assessment (HTA) Database.

104. [Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy]

[Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy] [Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy] [Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy] Soto N, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Soto N, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de

2017 Health Technology Assessment (HTA) Database.

105. Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. (Full text)

Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. To determine the incidence rates of sudden unexpected death in epilepsy (SUDEP) in different epilepsy populations and address the question of whether risk factors for SUDEP have been identified.Systematic review of evidence; modified Grading (...) Recommendations Assessment, Development, and Evaluation process for developing conclusions; recommendations developed by consensus.Findings for incidence rates based on 12 Class I studies include the following: SUDEP risk in children with epilepsy (aged 0-17 years) is 0.22/1,000 patient-years (95% confidence interval [CI] 0.16-0.31) (moderate confidence in evidence). SUDEP risk increases in adults to 1.2/1,000 patient-years (95% CI 0.64-2.32) (low confidence in evidence). The major risk factor for SUDEP

2017 EvidenceUpdates PubMed

106. Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy. (Full text)

Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy. This is an updated version of the original Cochrane review published in 2015, Issue 10.Severe myoclonic epilepsy in infants (SMEI), also known as Dravet syndrome, is a rare, refractory form of epilepsy, for which stiripentol (STP) has been recently licensed as add-on therapy.To evaluate the efficacy and tolerability of STP and other antiepileptic drug treatments (including ketogenic diet) for patients with SMEI.For (...) the latest update we searched the Cochrane Epilepsy Group Specialized Register (20 December 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 20 December 2016), MEDLINE (Ovid, 1946 to 20 December 2016) and ClinicalTrials.gov (20 December 2016). Previously we searched the World Health Organization (WHO) International Clinical Trials Registry Platform ICTRP, but this was not usable at the time of this update. We also searched

2017 Cochrane PubMed

107. Topiramate monotherapy for juvenile myoclonic epilepsy. (Full text)

Topiramate monotherapy for juvenile myoclonic epilepsy. Topiramate is a newer broad-spectrum antiepileptic drug (AED). Some studies have shown the benefits of topiramate monotherapy in the treatment of juvenile myoclonic epilepsy (JME). However, there are no current systematic reviews to determine the efficacy and tolerability of topiramate monotherapy in people with JME. This is an updated version of the original Cochrane Review published in Issue 12, 2015.To evaluate the efficacy (...) and tolerability of topiramate monotherapy in the treatment of JME.For the latest update, on 21 February 2017 we searched Cochrane Epilepsy's Specialized Register, CENTRAL, MEDLINE, and ClinicalTrials.gov. We also searched ongoing trials registers, reference lists and relevant conference proceedings, and contacted study authors and pharmaceutical companies.We included randomized controlled trials (RCTs) investigating topiramate monotherapy versus placebo or other AED treatment for people with JME

2017 Cochrane PubMed

108. Pregabalin Zentiva k.s. - neuropathic pain, epilepsy, generalised anxiety disorder

Pregabalin Zentiva k.s. - neuropathic pain, epilepsy, generalised anxiety disorder 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 15 December 2016 EMA/14344/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment (...) of neuropathic pain, epilepsy and generalised anxiety disorder (GAD) The legal basis for this application refers to: Generic application (Article 10(1) of Directive No 2001/83/EC). The application submitted is composed of administrative information, complete quality data and a bioequivalence study with the reference medicinal product Lyrica instead of non-clinical and clinical unless justified otherwise. Information on paediatric requirements Not applicable Information relating to orphan market exclusivity

2017 European Medicines Agency - EPARs

109. Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. (Full text)

Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. This is an updated version of the original Cochrane Review published in Issue 2, 2002 and its subsequent updates in 2010 and 2015.Epilepsy is a common neurological condition in which recurrent, unprovoked seizures are caused by abnormal electrical discharges from the brain. It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to become (...) with partial onset seizures (simple partial, complex partial, or secondarily generalised tonic-clonic seizures), or generalised tonic-clonic seizures, with or without other generalised seizure types.For the latest update we searched the Cochrane Epilepsy Group's Specialised Register (1st November 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 1st November 2016), MEDLINE (Ovid, 1946 to 1 November 2016), ClinicalTrials.gov (1 November

2017 Cochrane PubMed

110. Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. (Full text)

Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. Poor adherence to antiepileptic medication is associated with increased mortality, morbidity and healthcare costs. In this review, we focus on interventions designed and tested in randomised controlled trials and quasi-randomised controlled trials to assist people with adherence to antiepileptic medication. This is an updated version of the original Cochrane review published in the Cochrane Library (...) , Issue 1, 2010.To determine the effectiveness of interventions aimed at improving adherence to antiepileptic medication in adults and children with epilepsy.For the latest update, on 4 February 2016 we searched the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO), MEDLINE (Ovid 1946 to 4 February 2016), CINAHL Plus (EBSCOhost 1937 to 4 February 2016), PsycINFO (EBSCOhost 1887 to 4 February

2017 Cochrane PubMed

111. Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients

Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Intravenous immunoglobulin (...) for treatment of intractable epilepsy in pediatric patients. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Health Problem: Intractable epilepsy is diagnosed in 5% to 20% of pediatric patients with new-onset epilepsy. If uncontrolled, seizures in childhood may have a detrimental or even catastrophic impact on the developing brain. A connection has been made between inflammatory processes and neurological disease, including epilepsy, which may present new therapeutic

2017 Health Technology Assessment (HTA) Database.

120. Cannabidiol (Epidioloex) - To treat rare, severe forms of epilepsy

Cannabidiol (Epidioloex) - To treat rare, severe forms of epilepsy Drug Approval Package: Epidiolex (Cannabidiol) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Epidiolex (Cannabidiol) Company: GW Research Ltd. Application Number: 210365 Orig 1 Approval Date: 07/27/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2017 FDA - Drug Approval Package